{"id":745058,"date":"2015-12-17T17:52:00","date_gmt":"2015-12-17T17:52:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/"},"modified":"2025-11-07T01:24:42","modified_gmt":"2025-11-07T06:24:42","slug":"mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/","title":{"rendered":"Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved BRIDION<sup><b>\u00ae<\/b><\/sup> (sugammadex) Injection 100 mg\/mL<br \/>\n      (equivalent to 108.8 mg\/mL sugammadex sodium) for the reversal of<br \/>\n      neuromuscular blockade (NMB) induced by rocuronium bromide and<br \/>\n      vecuronium bromide in adults undergoing surgery.\n    <\/p>\n<p>\n      BRIDION works differently than neostigmine, an agent used to reverse<br \/>\n      non-depolarizing neuromuscular blocking agents (NMBAs) by increasing the<br \/>\n      neurotransmitter acetylcholine at the neuromuscular junction. BRIDION<br \/>\n      forms a complex with the non-depolarizing NMBAs rocuronium and<br \/>\n      vecuronium, thereby removing these agents from the neuromuscular<br \/>\n      junction and facilitating the return of muscle function. Unlike<br \/>\n      neostigmine, BRIDION can be used to reverse different levels of<br \/>\n      rocuronium and vecuronium-induced NMB, including deep block (1-2<br \/>\n      post-tetanic counts [PTCs]).\n    <\/p>\n<p>\n      \u201cThe FDA approval of BRIDION reflects Merck\u2019s continued commitment to<br \/>\n      develop medicines that address unmet needs,\u201d said Dr. David Michelson,<br \/>\n      vice president, Neurosciences, Merck Research Laboratories. \u201cWith<br \/>\n      BRIDION, we now have a new option with a different mechanism of action<br \/>\n      to reverse neuromuscular blockade induced by rocuronium and vecuronium<br \/>\n      in adults undergoing surgery.\u201d\n    <\/p>\n<p>\n      BRIDION is contraindicated in patients with known hypersensitivity to<br \/>\n      sugammadex or any of its components. Hypersensitivity reactions that<br \/>\n      occurred varied from isolated skin reactions to serious systemic<br \/>\n      reactions and have occurred in patients with no prior exposure to<br \/>\n      sugammadex.\n    <\/p>\n<p>\n      \u201cAnesthesia professionals have a new option in the clinical care of<br \/>\n      surgical patients,\u201d said Dr. Ronald D. Miller, professor emeritus,<br \/>\n      Department of Anesthesia &amp; Perioperative Care, University of California,<br \/>\n      San Francisco. \u201cWhen surgical procedures end with patients in deep<br \/>\n      block, as a result of rocuronium or vecuronium administration, BRIDION<br \/>\n      provides a unique reversal option to restore neuromuscular function.\u201d\n    <\/p>\n<p>\n      <b>BRIDION Clinical Studies<\/b>\n    <\/p>\n<p>\n      One hundred fifty-seven patients were evaluated in a phase 3,<br \/>\n      multicenter, randomized, parallel-group, active-controlled safety<br \/>\n      assessor-blinded clinical study. In the study, patients received either<br \/>\n      rocuronium or vecuronium and underwent elective surgical procedures<br \/>\n      under general anesthesia that required endotracheal intubation and<br \/>\n      maintenance of neuromuscular blockade. At 1-2 PTCs (deep block), after<br \/>\n      the last dose of rocuronium or vecuronium, 4 mg\/kg BRIDION or 70 mcg\/kg<br \/>\n      neostigmine was administered. The time from the start of administration<br \/>\n      of BRIDION or neostigmine to recovery of the train-of-four (T4\/T1) ratio<br \/>\n      of 0.9 was assessed. Generally, a T4\/T1 ratio \u22650.9 correlates with<br \/>\n      recovery from neuromuscular blockade. Neostigmine was not expected to<br \/>\n      reverse neuromuscular blockade at a depth of 1-2 PTCs.\n    <\/p>\n<p>\n      Patients treated with BRIDION achieved rapid recovery of neuromuscular<br \/>\n      function from rocuronium-induced (n=37) deep block (1-2 PTCs) in a<br \/>\n      median time of 2.7 minutes with a 25th and 75th percentiles of 2.1 and<br \/>\n      4.3 minutes respectively, and from vecuronium-induced (n=47) deep block<br \/>\n      in a median time of 3.3 minutes with a 25th and 75th percentiles of 2.3<br \/>\n      and 6.6 minutes, respectively. There were 7 and 6 censored observations<br \/>\n      in the rocuronium and vecuronium groups, respectively.\n    <\/p>\n<p>\n      An additional phase 3, multicenter, randomized, parallel-group,<br \/>\n      active-controlled safety assessor-blinded clinical study evaluated 189<br \/>\n      patients who received either rocuronium or vecuronium and underwent<br \/>\n      elective surgical procedures under general anesthesia that required<br \/>\n      endotracheal intubation and maintenance of neuromuscular blockade. At<br \/>\n      the reappearance of the second twitch (moderate block), after the last<br \/>\n      dose of rocuronium or vecuronium, 2\u00a0mg\/kg BRIDION or 50\u00a0mcg\/kg<br \/>\n      neostigmine was administered. The time from the start of administration<br \/>\n      of BRIDION or neostigmine to recovery of the train-of-four (T4\/T1) ratio<br \/>\n      of 0.9 was assessed.\n    <\/p>\n<p>\n      Patients treated with BRIDION (n=48) achieved faster recovery of<br \/>\n      neuromuscular function from rocuronium-induced moderate block in a<br \/>\n      median time of 1.4 minutes with a quartile 1 and quartile 3 of 1.2 and<br \/>\n      1.7 minutes, respectively, versus a median time of 21.5 minutes with a<br \/>\n      quartile 1 and quartile 3 of 9.8 and 42.0 minutes, respectively with<br \/>\n      neostigmine (n=48). Reversal of vecuronium-induced moderate NMB with<br \/>\n      BRIDION (n=48) occurred in a median time of 2.1 minutes with a quartile<br \/>\n      1 and quartile 3 of 1.8 and 3.4 minutes, respectively, versus 29.0<br \/>\n      minutes with a quartile 1 and quartile 3 of 12.2 and 76.2 minutes,<br \/>\n      respectively with neostigmine (n=45).\n    <\/p>\n<p>\n      <b>Selected Safety Information about BRIDION<\/b>\n    <\/p>\n<p>\n      Potentially serious hypersensitivity reactions, including anaphylaxis,<br \/>\n      have occurred in patients treated with BRIDION. In a clinical study,<br \/>\n      anaphylaxis occurred in 0.3 percent (n=1\/299) of healthy volunteers<br \/>\n      treated with BRIDION. Observe patients for an appropriate period of time<br \/>\n      after administration and take the necessary precautions. Anaphylaxis has<br \/>\n      also been reported in the post-marketing setting. Clinical features in<br \/>\n      anaphylaxis reports have included dermatologic symptoms; hypotension<br \/>\n      often requiring the use of vasopressors; and prolonged hospitalization<br \/>\n      and\/or the use of additional respiratory support until full recovery.\n    <\/p>\n<p>\n      Cases of marked bradycardia, some of which have resulted in cardiac<br \/>\n      arrest, have been observed within minutes after the administration of<br \/>\n      BRIDION. Monitor for hemodynamic changes and treat with anticholinergic<br \/>\n      agents, such as atropine, if clinically significant bradycardia is<br \/>\n      observed. Ventilatory support is mandatory for patients until adequate<br \/>\n      spontaneous respiration is restored and the ability to maintain a patent<br \/>\n      airway is assured. Should neuromuscular blockade persist after BRIDION<br \/>\n      or recur following extubation, take appropriate steps to provide<br \/>\n      adequate ventilation.\n    <\/p>\n<p>\n      In clinical trials, a small number of patients experienced a delayed or<br \/>\n      minimal response to BRIDION. Monitor ventilation until recovery occurs.\n    <\/p>\n<p>\n      A minimum waiting time is necessary before re-administration of a<br \/>\n      steroidal neuromuscular blocking agent after administration of BRIDION.<br \/>\n      If neuromuscular blockade is required before the recommended waiting<br \/>\n      time has elapsed, use a nonsteroidal neuromuscular blocking agent.\n    <\/p>\n<p>\n      Due to the administration of BRIDION, certain drugs, including hormonal<br \/>\n      contraceptives, could become less effective due to a lowering of the<br \/>\n      (free) plasma concentrations. Consider re-administration of the other<br \/>\n      drug, administration of a therapeutic equivalent drug, and\/or<br \/>\n      non-pharmacological interventions as appropriate.\n    <\/p>\n<p>\n      Recurrence of neuromuscular blockade may occur due to displacement of<br \/>\n      rocuronium or vecuronium from BRIDION by other drugs. Mechanical<br \/>\n      ventilation may be required. Stop the administration of the drug which<br \/>\n      caused displacement, if being administered by infusion.\n    <\/p>\n<p>\n      The use of lower than recommended doses of BRIDION may lead to an<br \/>\n      increased risk of recurrence of neuromuscular blockade and is not<br \/>\n      recommended. Also, when drugs which potentiate neuromuscular blockade<br \/>\n      are used in the post-operative phase, recurrence of neuromuscular<br \/>\n      blockade is possible.\n    <\/p>\n<p>\n      BRIDION doses of up to 16 mg\/kg were associated with increases in<br \/>\n      activated partial thromboplastin time and prothrombin time\/international<br \/>\n      normalized ratio. Carefully monitor coagulation parameters in patients<br \/>\n      with known coagulopathies; being treated with therapeutic<br \/>\n      anticoagulation; receiving thromboprophylaxis drugs other than heparin<br \/>\n      and low molecular weight heparin; or receiving thromboprophylaxis drugs<br \/>\n      and who then receive a dose of 16 mg\/kg sugammadex.\n    <\/p>\n<p>\n      BRIDION is not recommended for use in patients with severe renal<br \/>\n      impairment, including those requiring dialysis. BRIDION also has not<br \/>\n      been studied for reversal following rocuronium or vecuronium<br \/>\n      administration in the ICU.\n    <\/p>\n<p>\n      Do not use BRIDION to reverse nonsteroidal neuromuscular blocking agents<br \/>\n      or steroidal neuromuscular blocking agents other than rocuronium or<br \/>\n      vecuronium.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u2265 10% of patients at a 2,<br \/>\n      4, or 16 mg\/kg BRIDION dose and higher than placebo rate) were vomiting<br \/>\n      (11 percent, 12 percent, or 15 percent versus placebo at 10 percent),<br \/>\n      pain (48 percent, 52 percent, or 36 percent versus placebo at 38<br \/>\n      percent), nausea (23 percent, 26 percent, or 23 percent versus placebo<br \/>\n      at 23 percent), hypotension (4 percent, 5 percent, or 13 percent versus<br \/>\n      placebo at 4 percent), and headache (7 percent, 5 percent, or 10 percent<br \/>\n      versus placebo at 8 percent).\n    <\/p>\n<p>\n      <b>BRIDION Availability<\/b>\n    <\/p>\n<p>\n      BRIDION is expected to be available in January 2016.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51246580&amp;newsitemid=20151217006586&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=d2a2b4c6e8928bb2d8af0cbf729358d6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51246580&amp;newsitemid=20151217006586&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=77857a160bcf52a7869363fda2c6d424\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51246580&amp;newsitemid=20151217006586&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=b5432b690250eda5386d500cc692a0ce\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51246580&amp;newsitemid=20151217006586&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=219a5f7c63ce2a0e5955e39ba2d126d7\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51246580&amp;newsitemid=20151217006586&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=21fdddf91a93beaa28fdafe2b95749bd\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51246580&amp;newsitemid=20151217006586&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=c3ae21cdc1f7050709c610d0fa8c610a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for BRIDION (sugammadex) Injection<br \/>\n      at <\/b><br \/><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fb%2Fbridion%2Fbridion_pi.pdf&amp;esheet=51246580&amp;newsitemid=20151217006586&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fb%2Fbridion%2Fbridion_pi.pdf&amp;index=7&amp;md5=130f9e73d369320fc0d8aab80ba37f6c\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/b\/bridion\/bridion_pi.pdf<\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151217006586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Pamela Eisele, 267-305-3558<br \/>Doris        Li, 908-740-1903<br \/>or<br \/>Investor Contacts:<br \/>Teri Loxam,        908-740-1986<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION \u00ae (sugammadex) Injection 100 mg\/mL (equivalent to 108.8 mg\/mL sugammadex sodium) for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION works differently than neostigmine, an agent used to reverse non-depolarizing neuromuscular blocking agents (NMBAs) by increasing the neurotransmitter acetylcholine at the neuromuscular junction. BRIDION forms a complex with the non-depolarizing NMBAs rocuronium and vecuronium, thereby removing these agents from the neuromuscular junction and facilitating the return of muscle function. Unlike neostigmine, BRIDION can be used to reverse different levels of rocuronium and vecuronium-induced NMB, including deep block (1-2 post-tetanic counts [PTCs]). \u201cThe FDA approval of BRIDION reflects Merck\u2019s continued commitment<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745058","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION \u00ae (sugammadex) Injection 100 mg\/mL (equivalent to 108.8 mg\/mL sugammadex sodium) for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION works differently than neostigmine, an agent used to reverse non-depolarizing neuromuscular blocking agents (NMBAs) by increasing the neurotransmitter acetylcholine at the neuromuscular junction. BRIDION forms a complex with the non-depolarizing NMBAs rocuronium and vecuronium, thereby removing these agents from the neuromuscular junction and facilitating the return of muscle function. Unlike neostigmine, BRIDION can be used to reverse different levels of rocuronium and vecuronium-induced NMB, including deep block (1-2 post-tetanic counts [PTCs]). \u201cThe FDA approval of BRIDION reflects Merck\u2019s continued commitment\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\\\/\",\"name\":\"Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-12-17T17:52:00+00:00\",\"dateModified\":\"2025-11-07T06:24:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION \u00ae (sugammadex) Injection 100 mg\/mL (equivalent to 108.8 mg\/mL sugammadex sodium) for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION works differently than neostigmine, an agent used to reverse non-depolarizing neuromuscular blocking agents (NMBAs) by increasing the neurotransmitter acetylcholine at the neuromuscular junction. BRIDION forms a complex with the non-depolarizing NMBAs rocuronium and vecuronium, thereby removing these agents from the neuromuscular junction and facilitating the return of muscle function. Unlike neostigmine, BRIDION can be used to reverse different levels of rocuronium and vecuronium-induced NMB, including deep block (1-2 post-tetanic counts [PTCs]). \u201cThe FDA approval of BRIDION reflects Merck\u2019s continued commitment","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:42+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/","name":"Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-12-17T17:52:00+00:00","dateModified":"2025-11-07T06:24:42+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s BRIDION\u00ae (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fcd13f3e-8af4-44a1-a9dc-4becf49501e7","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745058\/revisions"}],"predecessor-version":[{"id":3674557,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745058\/revisions\/3674557"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745058"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}